Published by Iain Gilbert on 24th April 2020
(Sharecast News) - Astrazeneca and Merck said their Lynparza prostate cancer treatment had met a second goal in a trial for patients suffering from the metastatic castration-resistant version of the disease.
URL: http://www.digitallook.com/dl/news/story/30574631/...